Session: SAT 677-696-Obesity Physiology & Epidemiology
Poster Board SAT-685
Methods: We explored the characteristics of a sample of extreme obese individuals entering a specialist community weight management service. Patients completed questionnaires assessing quality of life and mental health (EQ5D, IWQOL-Lite and HADS), and sleep (PSQI and Epworth Sleepiness Scale). The sample included 270 individuals aged 18-80y (mean 43.5y SD=12.4).
Results: Mean baseline weight was 131.9kg (SD=24.5) and mean BMI 47.0kg/m2 (SD=7.8) Mean blood pressure was 141/85mmHg (SD=18/12) and mean waist circumference was 132cm (SD=24.5). The sample was predominantly White European (90%), female (75%), with 62% employed, 23% unemployed, 8% retired and 7% studying. The majority of the sample had children (88%), 51% were married, 23% single, 14% lived with a partner, 8% divorced, and 4% widowed. Smoking was prevalent (26% current smokers), with 14% being ex-smokers and 60% never smokers. Regular alcohol consumption was reported by 65%. The majority had taken medication to manage their weight (81%). The co-morbidities present were: type 2 diabetes (26.3%), obstructive sleep apnoea (25%), cardiovascular disease (11%), arthritis (23%), and hypertension (34%). The majority had a perceived low quality of life with 68% having an IWQOL-Lite total score below 50%, with a sample mean of 40% (IQR= 21-56). The mean EQ5D health score was low at 44%, whereby 100% represents optimum health. Anxiety and depression were highly prevalent with 70% scoring within the clinical case range for anxiety and 66% for depression. Perceived sleep quality was low with 60% reporting bad sleep, of whom 23% reported very bad sleep. The amount of sedentary time was also high with self-reported means of 6.7h (SD=3.9) on a weekday and 6.5h (SD=3.5) on a weekend day.
Conclusions: Findings indicate that this is a sample with very complex medical and psychological needs and highlights areas to be addressed (including smoking, sleep quality, mood, and other co-morbidities) in the multidisciplinary management of these patients.
Disclosure: ST: Clinical Researcher, Lilly USA, LLC, Clinical Researcher, Novo Nordisk. Nothing to Disclose: AJ, AB, MH, AW, RD, AG, GA, GNT
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters